search text   Advanced Search

This Article Abstract Full Text (PDF) P3Rs: Submit a response Alert me when this article is cited Alert me when P3Rs are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Lee, B. H. Search for Related Content PubMed Articles by Lee, B. H. Related Collections Premature & Newborn

Adverse Neonatal Outcomes Associated With Antenatal Dexamethasone Versus Antenatal Betamethasone

^a Division of Neonatal-Perinatal Medicine, Emory University School of Medicine, Atlanta, Georgia
^b Research Triangle Institute, Research Triangle Park, North Carolina
^c National Institute of Child Health and Human Development, Washington, DC

	ABSTRACT

TOP ABSTRACT METHODS RESULTS DISCUSSION Conclusion REFERENCES

 
OBJECTIVE. Antenatal dexamethasone and betamethasone may not be equally efficacious in the prevention of adverse neonatal outcomes. We compared the risks of periventricular leukomalacia (PVL), intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP), and neonatal death among very low birth weight infants who were exposed to dexamethasone, betamethasone, or neither steroid.

METHODS. Infants (401–1500 g) in the National Institute of Child Health and Human Development Neonatal Research Network were studied. Multivariate logistic regression analyses compared the 3 groups with regard to PVL, IVH, ROP, and neonatal death, adjusting for network center and selected covariates.

RESULTS. A total of 3600 infants met entry criteria. Compared with no antenatal steroids, there were trends for a reduced risk for PVL associated with dexamethasone and betamethasone but no difference in risk between dexamethasone and betamethasone. Dexamethasone reduced the risk for IVH and severe IVH, compared with no antenatal steroid exposure. Betamethasone reduced the risk for IVH, severe IVH, and neonatal death, compared with no antenatal steroids. Compared with betamethasone, dexamethasone had a statistically significant increased risk for neonatal death. There were trends for greater risks associated with dexamethasone compared with betamethasone for IVH and severe ROP.

CONCLUSIONS. Betamethasone was associated with a reduced risk for neonatal death, with trends of decreased risk for other adverse neonatal outcomes, compared with dexamethasone. It may be in the best interest of neonates to receive betamethasone rather than dexamethasone when available.

Key Words: antenatal glucocorticoids • dexamethasone • betamethasone • neonatal morbidity • neonatal mortality

Abbreviations: IVH—intraventricular hemorrhage • PVL—periventricular leukomalacia • ROP—retinopathy of prematurity • NICHD—National Institute of Child Health and Human Development • VLBW—very low birth weight • GA—gestational age • OR—odds ratio • CI—confidence interval • PROM—prolonged rupture of membranes

One of the chief advances in perinatal medicine in the past 25 years has been the administration of antenatal steroids for induction of fetal lung maturity to pregnant women with imminent delivery of an infant at 24 to 34 weeks' gestation. First introduced by Liggins in 1972, antenatal corticosteroid use has been associated with a reduced risk for respiratory distress syndrome, intraventricular hemorrhage (IVH), and overall neonatal mortality.^1–7 Currently, the only antenatal steroids that are used for such therapy are the fluorinated steroids dexamethasone and betamethasone, with specific antenatal steroid usage patterns being dependent on commercial availability, institutional formulary listing, and provider preference.

Animal and human studies have raised concerns that dexamethasone, when compared with betamethasone, may be associated with an increased risk for adverse neonatal neurologic outcomes.^8,9 Of particular concern was the finding by Baud et al⁸ that dexamethasone, compared with betamethasone, was associated with an increased risk for cystic periventricular leukomalacia (PVL), a degenerative process that involves the white matter of the brain and is associated with cerebral palsy, mental retardation, and other adverse long-term neurobehavioral outcomes. Several studies have investigated the effects of antenatal steroids on other adverse neonatal outcomes, with conflicting results. In general, antenatal steroids have been associated with both decreased and unaltered risk for retinopathy of prematurity (ROP)^8,10,11; an increased, decreased, and unaltered risk for neonatal sepsis^3,5,7; and an increased, decreased, and unaltered risk for necrotizing enterocolitis.^3,7,8,12 However, other than the observational study by Baud et al,⁸ no studies have compared directly neonatal morbidities and mortality in infants who are exposed to dexamethasone or betamethasone.

Using registry data from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, the current study was designed with the primary aim of determining whether there is a difference in risk for developing PVL among very low birth weight (VLBW) infants who are exposed to dexamethasone compared with betamethasone. The secondary aim of this study was to compare the incidences of IVH, ROP, and neonatal death among VLBW infants who are exposed to dexamethasone versus betamethasone.

	METHODS

TOP ABSTRACT METHODS RESULTS DISCUSSION Conclusion REFERENCES

 
Data for this historical cohort study were abstracted from the NICHD Neonatal Research Network registry of VLBW infants who weighed 401 to 1500 g at birth and were born at or admitted before 14 days of life at participating centers.¹³ In January 2002, the network began monitoring the type of antenatal steroid used in participating centers, with current usage patterns of dexamethasone and betamethasone being 40% and 60%, respectively. The exposures of interest were dexamethasone or betamethasone exposure (neonates with no antenatal steroid exposure served as a referent group) with the primary outcome of PVL. Secondary outcomes were the presence of an IVH, severe IVH, ROP, severe ROP, and neonatal death.

Patients
Infants who had a birth weight between 401 g and 1500 g and were born at network centers between January 1, 2002, and April 30, 2003, were included in this study. Infants were excluded when they had a congenital anomaly, chromosomal anomaly, inborn error of metabolism, intrauterine infection, or exposure to both dexamethasone and betamethasone or died in the first 12 hours of life. Gestational age (GA) was determined by best obstetric estimates from last menstrual period, standard obstetric parameters, and ultrasonography. Outborn infants were excluded because documentation of antenatal steroid exposure from referring hospitals could not be reliably ascertained by the registry.

Exposure Definition
Antenatal steroid exposure was defined as maternal receipt of either dexamethasone or betamethasone during the admission for delivery. A complete course of dexamethasone was defined as four 6-mg intramuscular doses of a commercially obtained product (GensiaSicor Pharmaceuticals, Inc, Irvine, CA; American Regent Laboratories, Shirley, NY; American Pharmaceutical Partners, Inc, Schaumburg, IL; Baxter, Deerfield, IL) given at 12-hour intervals. A complete course of betamethasone was defined as two 12-mg intramuscular doses of a commercially obtained product (Schering-Plough, Kenilworth, NJ) given at 24-hour intervals. Dexamethasone and betamethasone were the only 2 agents used for antenatal steroid prophylaxis.

Outcome Definitions
PVL or cystic cerebral parenchymal lesions were diagnosed by pediatric radiologists using cranial sonography during the NICU hospitalization. Only infants who underwent at least 1 cranial sonogram at 36 weeks' postmenstrual age were included in PVL analyses, as PVL may not become ultrasonographically evident until 36 weeks' postmenstrual age. Neonatal death was defined as death within the first 28 days of life, given survival for the first 12 hours of life. IVH was defined using Papile's classification,¹⁴ as diagnosed by pediatric radiologists using cranial sonography during the NICU hospitalization; severe IVH was defined as grade III or IV IVH. Only infants who underwent at least 1 cranial sonogram were included in IVH analyses. Severe ROP was defined as ROP with threshold or plus disease or that required surgical intervention before discharge or transfer. Only infants who received at least 1 ophthalmologic examination were included in ROP analyses.

Statistical Analysis
Continuous variables were summarized with arithmetic means and SDs. Preliminary logistic and linear regression models were performed on discrete and continuous variables, respectively, using only network center as an additional covariate to assess for associations between antenatal steroid exposure and outcomes. Unconditional multivariate logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of either dexamethasone or betamethasone with outcomes; network centers were coded as dummy covariates, with the center with the lowest incidence of the analyzed outcome being the reference group. Additional covariates were selected on the basis of the biological plausibility of and importance to the modeled associations^15–17; these were gestational hypertension (preexisting, preeclamptic, or eclamptic), prolonged rupture of membranes (PROM) >18 hours, mode of delivery (cesarean versus vaginal), infant gender, number of gestations (singleton versus multiple), and birth weight by 250-g increments. Maternal marital status (single versus married), maternal race (white versus nonwhite), and receipt of at least 1 prenatal care visit also were included to model maternal socioeconomic status. GA was not included in the models because of the high degree of colinearity between birth weight and GA. Postnatal covariates such as early-onset sepsis, receipt of indomethacin within the first 24 hours of life, and patent ductus arteriosus that required surgical or medical intervention were not included in the reported model because of the inability to define definitively either their temporal relation to the study outcomes and/or their potential roles as mediating events in the causal chain relating antenatal steroid exposure and outcomes. Additional subanalyses were performed using conditional logistic regression models that stratified antenatal steroid exposure into partial and complete/multiple courses. The results of these dose-dependent conditional analyses, however, did not differ from that of the primary unconditional models; therefore, only the results from the primary models are presented. For all tests, statistical significance was established at a P < .05. All statistical analyses were performed using Statistical Analysis System software, version 8.02 (SAS Institute, Cary, NC).

Sample Size Calculation
Assuming a baseline incidence of PVL of 5% among VLBW infants¹⁸ and a 50% reduction in PVL risk associated with betamethasone versus no antenatal steroid exposure,⁸ it was estimated that a sample size of 938 VLBW infants with a 1:1 ratio of dexamethasone to betamethasone exposure was needed to detect a 30% increase in the risk for PVL associated with dexamethasone compared with no antenatal steroid exposure, with a 2-tailed of 5% and a power of 80%. This would provide for the detection of an absolute difference of 4 percentage points in PVL incidence rates between dexamethasone and betamethasone (ie, 6.5% versus 2.5%), or an OR of 2.71, with the allowed type I and type II errors.

	RESULTS

TOP ABSTRACT METHODS RESULTS DISCUSSION Conclusion REFERENCES

 
From January 1, 2002, to April 30, 2003, a total of 4939 VLBW infants were registered in the network database, 74% of whom received antenatal steroids. Within this group, 3600 VLBW infants met study entry criteria, 635 (18%) of whom received no antenatal steroids, 1227 (34%) of whom received dexamethasone, and 1738 (48%) of whom received betamethasone. Among infants who were exposed to dexamethasone, 445 (36%) received a partial course, 760 (62%) received a complete course, 20 (2%) received multiple courses, and 2 did not have documentation of the number of courses received. Among infants who were exposed to betamethasone, 428 (25%) received a partial course, 1228 (71%) received a complete course, 79 (4%) received multiple courses, and 3 did not have documented course numbers. A total of 2559 (71.1%) infants received at least 1 ophthalmologic examination, and 2947 (81.9%) underwent a cranial sonogram by 36 weeks' postmenstrual age.

Baseline Maternal and Neonatal Characteristics
Maternal characteristics are shown in Table 1. By preliminary regression modeling adjusting only for center, there were statistically significant differences among the 3 groups with regard to marital status, race, and receipt of prenatal care. Mothers who received antenatal steroids were more likely to be married, be white, and receive at least 1 prenatal care visit compared with those who did not.

	DISCUSSION

TOP ABSTRACT METHODS RESULTS DISCUSSION Conclusion REFERENCES

This is the largest study to date to evaluate the differential neonatal effects of dexamethasone and betamethasone. In the only other human study that directly compared outcomes that are associated with dexamethasone versus betamethasone, Baud et al⁸ reported in an observational study that betamethasone but not dexamethasone was associated with a reduced risk for cystic PVL, after adjusting for selected covariates. In contrast to the findings by Baud et al, we found no differences in risk for cystic PVL associated with dexamethasone or betamethasone compared with no antenatal steroid exposure or between dexamethasone and betamethasone. However, in the multicenter study by Baud et al, there was no adjustment made for study center in the PVL analyses; this is of note given that the center with the lowest rate of cystic PVL also was the center with the highest utilization of betamethasone.

Consistent with previous reports,^2,3 this study found statistically significant reductions in risk for IVH and severe IVH associated with both dexamethasone and betamethasone compared with no antenatal exposure. Notably, we found that both dexamethasone and betamethasone were equally efficacious in reducing the risk for IVH and severe IVH, consistent with the findings by Baud et al.⁸ However, we found a significant reduction in risk for neonatal death associated with betamethasone but not dexamethasone, compared with no exposure to antenatal steroids, a finding similar to that reported in the Cochrane meta-analysis by Crowley.⁷ Furthermore, dexamethasone was associated with an increased risk for neonatal death when compared with betamethasone as well. Neonatal death was defined as death within the first 28 days of life, in an attempt to remove confounding effects by postnatal risk factors for death beyond the immediate neonatal period. In addition, we excluded infants who died within the first 12 hours of life in an attempt to reduce the effects of catastrophic perinatal confounders, such as placental abruption or perinatal asphyxia, from antenatal steroid analyses. Therefore, the differences in neonatal mortality between dexamethasone and betamethasone may be related to effects of the antenatal steroid itself.

We also assessed the associations of antenatal steroids on ROP, as previous studies have documented a decreased risk for ROP associated with antenatal steroid exposure,^10,11,19,20 possibly related to the glucocorticoid-mediated acceleration of retinal vascular maturation and inhibition of tumor necrosis factor production, a key factor in inflammatory and angiogenic mechanisms.²¹ It is unlikely that dexamethasone has a direct toxic effect on the developing retina; Rotschild et al¹⁹ previously reported with a neonatal ROP mouse model that there was no alteration in retinal development associated with dexamethasone. To date, no comparative studies have adjusted for selected risk factors in comparing the incidence of severe ROP associated with dexamethasone and betamethasone. The current study found a statistically nonsignificant trend toward a 50% increase in risk for severe ROP associated with dexamethasone compared with betamethasone. The causes for this potential differential retinotoxic effect between dexamethasone and betamethasone remain unclear and warrant additional study.

The suggestion that dexamethasone may be neurologically detrimental when compared with betamethasone has been raised by other studies. Rayburn et al⁹ reported that mice that were exposed to dexamethasone had decreased neurobehavioral functionality, specifically with regard to anxiety and memory, when compared with mice that were given betamethasone. In human subjects, Jobe and Soll,²² using the data from Crowley's meta-analysis, documented that although both dexamethasone and betamethasone were associated with statistically significant reductions in risk for IVH, only betamethasone was statistically associated with a reduction in risk for death. Similarly, Baud et al⁸ reported in their unadjusted analyses that betamethasone and not dexamethasone was associated with a reduction in death. Dexamethasone and betamethasone differ only in the orientation of the methyl group at position 16, being in the configuration in dexamethasone and in the ß configuration in betamethasone; however, this structural difference could be responsible for marked differences in nongenomic effects. In an in vitro study, Buttgereit et al²³ found that dexamethasone was 5 times more potent than betamethasone in inhibiting thymocyte respiration. Similarly, there may be genomic and specific nongenomic differences between dexamethasone and betamethasone, including the expression of glutamate receptors and ion transport channels.^24–26 There have also been concerns raised regarding the possible neurotoxic effects of the sodium metabisulfite preservative that is used in commercially available dexamethasone.^27,28 The mechanisms of sulfite neurotoxicity may be related to the formation of cysteine-S-sulfate, a potentially excitotoxic metabolite of sulfites that is structurally similar to glutamate, and the generation of oxygen and sulfur radicals. However, there are questions as to whether the dose of sulfites administered antenatally to the mother has concentrated effects at the fetal level. Furthermore, postnatal exposure to sulfite preservatives in routine parental amino acid formulations and cardiovascular medications theoretically provides a higher exposure to sulfites than that in antenatal dexamethasone, making the contribution of sulfites in commercial dexamethasone less significant than other potential agents with regard to hypothesized induced brain injury.

There are several considerations that should be addressed when interpreting the findings of the current study, mostly related to the retrospective nature of the study design. Multivariate analyses are able to adjust for known, measurable covariates for the outcomes of interest. Significant unknown confounders may have affected our findings; this must be kept in mind when interpreting our results and when considering future studies. With regard to known confounders, a major weakness to our study was the lack of inclusion of chorioamnionitis, a major risk factor for PVL^29,30 as a covariate, as the network database does not routinely collect data on this variable. Although the presence of PROM >18 hours was used as a proxy for chorioamnionitis, it is an incomplete measure. This weakness may have introduced a nondifferential misclassification bias that would have biased the PVL analyses toward the null value. Similarly, other known postnatal risk factors for adverse neonatal outcomes, including postnatal steroid exposure,^31–33 were not included in the models because of the inability to define consistently the temporal relationship between postnatal risk factors and study outcomes; these limitations also must be considered when interpreting our results. The validity of the PVL and IVH definitions that were used in this study also can be debated given concerns of the incompleteness of the current IVH staging method, crude conceptualization of PVL, and exclusion of ventricular enlargement and cerebellar or brainstem lesions, as done in this study, to reflect accurately the spectrum of neonatal white matter damage that neuropathologically correlates to neurodevelopmental morbidity.³⁴ Furthermore, the reliability of neonatal cranial ultrasounds for routine detection of neuropathologic entities may be lower than believed by neonatal practitioners.^35,36 For these reasons, we are planning a neurodevelopmental follow-up of this cohort when they reach 18 to 22 months' corrected age to assess further the possible differential long-term neurodevelopmental effects of dexamethasone and betamethasone not reflected by neonatal cranial ultrasound imaging.

	Conclusion

TOP ABSTRACT METHODS RESULTS DISCUSSION Conclusion REFERENCES

 
The current study provides evidence that betamethasone statistically reduces the risk for neonatal death, whereas dexamethasone does not, in agreement with the findings by Crowley.⁷ Furthermore, there were notable trends for a reduced risk for adverse neonatal outcomes associated with betamethasone compared with dexamethasone for IVH and severe ROP. However, there were no alterations in risk for PVL associated with either antenatal steroid compared with each other or with the absence of antenatal steroid exposure. On the basis of these findings and those of other authors, a randomized, clinical trial on the differing fetal and neonatal effects of dexamethasone and betamethasone should be considered. Given that no such clinical trial yet has been performed, the findings of the current study have implications regarding the selection of antenatal steroid for standard prophylactic purposes. Given the current body of literature favoring the use of betamethasone versus dexamethasone, it may be in the best interest of neonates to receive antenatal betamethasone rather than antenatal dexamethasone when the option is available to do so.

	ACKNOWLEDGMENTS

 
This study was conducted for and supported by the NICHD (Bethesda, MD).

We thank Augusto Sola, MD, for his invaluable contributions to the study design.

Members of the NICHD Neonatal Research Network (1996–2005), Steering Committee Chairman Alan H. Jobe, MD, PhD. University of California at San Diego (U10 HD40461): Neil N. Finer, MD^*, Maynard Rasmussen, MD, Wade Rich; Case Western Reserve University (U10 HD21364): Michele Walsh, MD^*, Avroy A. Fanaroff, MB, BCh, Nancy Newman, RN; University of Cincinnati (U10 HD27853): Edward F. Donovan, MD^*, Vivek Narendran MD, MRCP, Cathy Grisby, RN; Duke University (U10 HD40492): Ronald N. Goldberg, MD^*, Michael Cotten, MD, Kathy Auten, RN; Emory University (U10 HD27851): Barbara J. Stoll, MD^*, Ellen Hale, RN; Indiana University (U10 HD27856): James A. Lemons, MD^*, Brenda Poindexter, MD, Lucy Miller, RN; University of Miami (U10 HD21373): Shahnaz Duara, MD^*, Emmalee S. Bandstra, MD, Ruth Everett, RN; NICHD: Rosemary D. Higgins, MD^*, James Hansen, MD; Research Triangle Institute (U10 HD36790): W. Kenneth Poole, PhD^*, Betty Hastings, Carolyn M. Petrie, MS; University of Rochester (U10 HD40521): Dale L. Phelps, MD^*, Ronnie Guillet, MD, PhD, Linda Reubens, RN; Stanford University (U10 HD27880): David K. Stevenson, MD^*, Krisa Van Meurs, MD, Bethany Ball, BS; University of Texas Health Science Center at Houston (U10 HD21373): Jon E. Tyson, MD, MPH^*, Kathleen Kennedy, MD, MPH, Georgia McDavid, RN; University of Texas Southwestern Medical Center (U10 HD40689): Abbot R. Laptook, MD^*, Walid Salhab, MD, Gay Hensley, RN; Wake Forest University: T. Michael O'Shea, MD^*, Robert Dillard, MD, Nancy Peters, RN; Wayne State University (U10 HD21385): Seetha Shankaran, MD^*, Ganesh Konduri, MD, Geraldine Muran, RN; Women and Infants Hospital (U10 HD27904): William Oh, MD^*, Barbara Stonestreet, MD, Angelita Hensman, RN; Yale University (U10 HD27871): Richard A. Ehrenkranz, MD^*, Patricia Gettner, RN; University of Alabama at Birmingham (U10 HD34216): Waldemar A. Carlo, MD^*, Namasivayam Ambalavanan, MD, Monica V. Collins, RN.

	FOOTNOTES

 
Accepted Oct 18, 2005.

Address correspondence to Ben H. Lee, MD, 2015 Uppergate Dr, Division of Neonatal-Perinatal Medicine, Atlanta, GA 30322-1028. E-mail: ben_lee{at}oz.ped.emory.edu

The authors have indicated they have no financial relationships relevant to this article to disclose.

^* Principal investigator.

	REFERENCES

TOP ABSTRACT METHODS RESULTS DISCUSSION Conclusion REFERENCES

 

1. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50 :515 –525[Abstract/Free Full Text]
2. Shankaran S, Bauer CR, Bain R, Wright LL, Zachary J. Relationship between antenatal steroid administration and grades III and IV intracranial hemorrhage in low birth weight infants. The NICHD Neonatal Research Network. Am J Obstet Gynecol. 1995;173 :305 –312[CrossRef][ISI][Medline]
3. Wright LL, Verter J, Younes N, et al. Antenatal corticosteroid administration and neonatal outcome in very low birth weight infants: the NICHD Neonatal Research Network. Am J Obstet Gynecol. 1995;173 :269 –274[CrossRef][ISI][Medline]
4. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA. 1995;273 :413 –418[Abstract]
5. Wells LR, Papile LA, Gardner MO, Hartenberger CR, Merker L. Impact of antenatal corticosteroid therapy in very low birth weight infants on chronic lung disease and other morbidities of prematurity. J Perinatol. 1999;19 :578 –581[CrossRef][Medline]
6. Leviton A, Dammann O, Allred EN, et al. Antenatal corticosteroids and cranial ultrasonographic abnormalities. Am J Obstet Gynecol. 1999;181 :1007 –1017[ISI][Medline]
7. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev. 2000;2 :CD000065[Medline]
8. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999;341 :1190 –1196[Abstract/Free Full Text]
9. Rayburn WF, Christensen HD, Gonzalez CL. A placebo-controlled comparison between betamethasone and dexamethasone for fetal maturation: differences in neurobehavioral development of mice offspring. Am J Obstet Gynecol. 1997;176 :842 –850[CrossRef][ISI][Medline]
10. The Italian ROP Study Group. Italian multicentre study on retinopathy of prematurity. Eur J Pediatr. 1997;156 :939 –943[CrossRef][ISI][Medline]
11. Higgins RD, Mendelsohn AL, DeFeo MJ, Ucsel R, Hendricks-Munoz KD. Antenatal dexamethasone and decreased severity of retinopathy of prematurity. Arch Ophthalmol. 1998;116 :601 –605[Abstract/Free Full Text]
12. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol. 1981;141 :276 –287[ISI][Medline]
13. Hack M, Horbar JD, Malloy MH, Tyson JE, Wright E, Wright L. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network. Pediatrics. 1991;87 :587 –597[Abstract/Free Full Text]
14. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 gm. J Pediatr. 1978;92 :529 –534[CrossRef][ISI][Medline]
15. Zupan V, Gonzalez P, Lacaze-Masmonteil T, et al. Periventricular leukomalacia: risk factors revisited. Dev Med Child Neurol. 1996;38 :1061 –1067[ISI][Medline]
16. Murphy DJ, Sellers S, MacKenzie IZ, Yudkin PL, Johnson AM. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet. 1995;346 :1449 –1454[CrossRef][ISI][Medline]
17. Deulofeut R, Sola A, Lee B, Buchter S, Rahman M, Rogido M. The impact of vaginal delivery in premature infants weighing less than 1,251 grams. Obstet Gynecol. 2005;105 :525 –531[Abstract/Free Full Text]
18. Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development Neonatal Research Network, January 1995 through December 1996. Pediatrics. 2001;107 :1 –8[Abstract/Free Full Text]
19. Rotschild T, Nandgaonkar BN, Yu K, Higgins RD. Dexamethasone reduces oxygen induced retinopathy in a mouse model. Pediatr Res. 1999;46 :94 –100[ISI][Medline]
20. Yossuck P, Yan Y, Tadesse M, Higgins RD. Dexamethasone and critical effect of timing on retinopathy. Invest Ophthalmol Vis Sci. 2000;41 :3095 –3099[Abstract/Free Full Text]
21. Yossuck P, Yan Y, Tadesse M, Higgins RD. Dexamethasone alters TNF-alpha expression in retinopathy. Mol Genet Metab. 2001;72 :164 –167[CrossRef][ISI][Medline]
22. Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol. 2004;190 :878 –881[CrossRef][ISI][Medline]
23. Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol. 1999;58 :363 –368[CrossRef][ISI][Medline]
24. McGowan JE, Sysyn G, Petersson KH, et al. Effect of dexamethasone treatment on maturational changes in the NMDA receptor in sheep brain. J Neurosci. 2000;20 :7424 –7429[Abstract/Free Full Text]
25. Helve O, Pitkanen OM, Andersson S, O'Brodovich H, Kirjavainen T, Otulakowski G. Low expression of human epithelial sodium channel in airway epithelium of preterm infants with respiratory distress. Pediatrics. 2004;113 :1267 –1272[Abstract/Free Full Text]
26. Wang ZM, Yasui M, Celsi G. Differential effects of glucocorticoids and mineralocorticoids on the mRNA expression of colon ion transporters in infant rats. Pediatr Res. 1995;38 :164 –168[ISI][Medline]
27. Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulfite in combination with peroxynitrite on neuronal cells. J Neurochem. 1998;71 :2431 –2438[ISI][Medline]
28. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res. 2001;50 :706 –711[ISI][Medline]
29. Yoon BH, Park CW, Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. Br J Obstet Gynecol. 2003;110 :124 –127
30. Rezaie P, Dean A. Periventricular leukomalacia, inflammation and white matter lesions within the developing nervous system. Neuropathology. 2002;22 :106 –132[CrossRef][ISI][Medline]
31. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104 :15 –21[Abstract/Free Full Text]
32. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000;83 :177 –181[CrossRef]
33. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350 :1304 –1313[Abstract/Free Full Text]
34. Paneth N. Classifying brain damage in preterm infants. J Pediatr. 1999;134 :527 –529[CrossRef][ISI][Medline]
35. Inder T, Huppi PS, Zientara GP, et al. Early detection of periventricular leukomalacia by diffusion-weighted magnetic resonance imaging techniques. J Pediatr. 1999;134 :631 –634[CrossRef][ISI][Medline]
36. Golomb MR, Dick PT, MacGregor DL, Armstrong DC, DeVeber GA. Cranial ultrasonography has a low sensitivity for detecting arterial ischemic stroke in term neonates. J Child Neurol. 2003;18 :98 –103[Abstract/Free Full Text]

This article has been cited by other articles:

				L. P. Wang and M. J. Paech Neuroanesthesia for the Pregnant Woman Anesth. Analg., July 1, 2008; 107(1): 193 - 200. [Abstract] [Full Text] [PDF]

				B. H. Lee, B. J. Stoll, S. A. McDonald, R. D. Higgins, and for the National Institute of Child Health and Hum Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants Exposed Prenatally to Dexamethasone Versus Betamethasone Pediatrics, February 1, 2008; 121(2): 289 - 296. [Abstract] [Full Text] [PDF]

				A. Elimian, D. Garry, R. Figueroa, A. Spitzer, V. Wiencek, and J. G. Quirk Antenatal Betamethasone Compared With Dexamethasone (Betacode Trial): A Randomized Controlled Trial Obstet. Gynecol., July 1, 2007; 110(1): 26 - 30. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) P3Rs: Submit a response Alert me when this article is cited Alert me when P3Rs are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Lee, B. H. Search for Related Content PubMed Articles by Lee, B. H. Related Collections Premature & Newborn

	Home | My Pediatrics | Journal Information | Current Issue | Past Issues | Subscriptions & Services | Contact Us Click here for faster international access © 2006 American Academy of Pediatrics. All rights reserved.